person · Reporting owner

PAUL STEVEN M

Disclosed activity across 7 companies

Tapewire entity: 13211
SEC CIK: 0001237564

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	April 01, 2022	April 05, 2022
ELI LILLY & CoLLY · Entity 2794	EVP, Science and Technology	December 31, 2009	February 03, 2010
Rapport Therapeutics, Inc.RAPP · Entity 4394	Director	June 10, 2026	June 10, 2026
Sage Therapeutics, Inc.SAGE · Entity 77038	Director	January 03, 2024	January 04, 2024
Seaport Therapeutics, Inc.SPTX · Entity 4799	Director	April 30, 2026	May 04, 2026
Voyager Therapeutics, Inc.VYGR · Entity 6271	Director	June 03, 2021	June 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date April 01, 2022 · Filed April 05, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,000	Ending reported balance After 2022-04-01 transaction · row 11 11 source rows · reconciled sequence Row 1 · 2022-04-01 · Exercise / conversion · Acquired 15,000 · Balance 16,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 2 · 2022-04-01 · Sale · Disposed 253 · Balance 15,747 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2: Sale prices ranged from $165.91 to $166.41. Row 3 · 2022-04-01 · Sale · Disposed 4,948 · Balance 10,799 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3: Sale prices ranged from $168.30 to $169.30. Row 4 · 2022-04-01 · Sale · Disposed 4,872 · Balance 5,927 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4: Sale prices ranged from $169.32 to $170.28. Row 5 · 2022-04-01 · Sale · Disposed 1,235 · Balance 4,692 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5: Sale prices ranged from $170.70 to $171.63. Row 6 · 2022-04-01 · Sale · Disposed 1,434 · Balance 3,258 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6: Sale prices ranged from $171.75 to $172.73. Row 7 · 2022-04-01 · Sale · Disposed 642 · Balance 2,616 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7: Sale prices ranged from $172.83 to $173.37. Row 8 · 2022-04-01 · Sale · Disposed 90 · Balance 2,526 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Row 9 · 2022-04-01 · Sale · Disposed 526 · Balance 2,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8: Sale prices ranged from $176.04 to $176.88. Row 10 · 2022-04-01 · Sale · Disposed 825 · Balance 1,175 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9: Sale prices ranged from $177.12 to $178.00. Row 11 · 2022-04-01 · Sale · Disposed 175 · Balance 1,000 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.33 · Expires 2022-06-21	Direct	0	Reported balance After 2022-04-01 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-04-01 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022.

F2: Sale prices ranged from $165.91 to $166.41.

F3: Sale prices ranged from $168.30 to $169.30.

F4: Sale prices ranged from $169.32 to $170.28.

F5: Sale prices ranged from $170.70 to $171.63.

F6: Sale prices ranged from $171.75 to $172.73.

F7: Sale prices ranged from $172.83 to $173.37.

F8: Sale prices ranged from $176.04 to $176.88.

F9: Sale prices ranged from $177.12 to $178.00.

ELI LILLY & Co

Report date December 31, 2009 · Filed February 03, 2010

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,000	Ending reported balance After 2009-12-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2009-12-22 · Gift · Disposed 8,553 · Balance 33,854 Row 2 · 2009-12-23 · Gift · Disposed 28,854 · Balance 5,000
Common StockSEC Table I · non-derivative	Indirectby wife	37,407	Last balance in matching sequence After 2009-12-23 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2009-12-22 · Gift · Acquired 8,553 · Balance 8,553 F1: Reporting person disclaims beneficial ownership of these shares. Row 4 · 2009-12-23 · Gift · Acquired 28,854 · Balance 37,407 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirect401(k)	909	Reported balance Holding disclosure · report date 2009-12-31 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 909
Common StockSEC Table I · non-derivative	Indirectby daughter	579	Reported balance Holding disclosure · report date 2009-12-31 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 579 F1: Reporting person disclaims beneficial ownership of these shares.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person disclaims beneficial ownership of these shares.

Rapport Therapeutics, Inc.

Report date June 10, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10	Direct	15,200	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Sage Therapeutics, Inc.

Report date January 03, 2024 · Filed January 04, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.67 · Expires 2034-01-03	Direct	3,971	Reported balance After 2024-01-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-01-03 · Grant · Acquired 3,971 · Balance 3,971 F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

Seaport Therapeutics, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	863,031	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Conversion · Acquired 67,031 · Balance 863,031 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	12,258	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 12,258 · Balance 12,258 F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	991,192	Reported balance After 2026-04-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-30 · Grant · Acquired 991,192 · Balance 991,192
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-04 · Conversion · Disposed 210,526 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.

F2: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

Voyager Therapeutics, Inc.

Report date June 03, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2031-06-03	Direct	15,000	Reported balance After 2021-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Karuna Therapeutics, Inc.

Report date March 18, 2024 · Filed March 18, 2024

Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,550	Reported balance After 2024-03-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-18 · Disposition to issuer · Disposed 2,046 · Balance 8,550 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-03-18 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2024-03-18 · Disposition to issuer · Disposed 8,550 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectSteve M. Paul Family 2021 Delaware Trust	0	Reported balance After 2024-03-18 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2024-03-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectThe Steven M Paul Revocable Trust	0	Reported balance After 2024-03-18 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2024-03-18 · Disposition to issuer · Disposed 33,882 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.
Common StockSEC Table I · non-derivative	IndirectSteven M. Paul Family 2024 Trust	0	Reported balance After 2024-03-18 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2024-03-18 · Disposition to issuer · Disposed 30,304 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Common StockSEC Table I · non-derivative	IndirectJann E. Paul GRAT III	0	Reported balance After 2024-03-18 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2024-03-18 · Disposition to issuer · Disposed 35,877 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.04 · Expires 2028-04-29	Direct	0	Reported balance After 2024-03-18 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-03-18 · Disposition to issuer · Disposed 136,094 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2028-08-08	Direct	0	Reported balance After 2024-03-18 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-03-18 · Disposition to issuer · Disposed 757,045 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-20	Direct	0	Reported balance After 2024-03-18 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-03-18 · Disposition to issuer · Disposed 449,463 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-28	Direct	0	Reported balance After 2024-03-18 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-03-18 · Disposition to issuer · Disposed 87,494 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-04-07	Direct	0	Reported balance After 2024-03-18 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-03-18 · Disposition to issuer · Disposed 15,205 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2019-06-26	Direct	0	Reported balance After 2024-03-18 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-03-18 · Disposition to issuer · Disposed 616,703 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2019-06-27	Direct	0	Reported balance After 2024-03-18 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2024-03-18 · Disposition to issuer · Disposed 71,121 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.72 · Expires 2030-02-13	Direct	0	Reported balance After 2024-03-18 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2024-03-18 · Disposition to issuer · Disposed 135,992 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F6: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.64 · Expires 2031-02-22	Direct	0	Reported balance After 2024-03-18 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2024-03-18 · Disposition to issuer · Disposed 161,850 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.97 · Expires 2032-02-16	Direct	0	Reported balance After 2024-03-18 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2024-03-18 · Disposition to issuer · Disposed 146,900 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $187.26 · Expires 2023-02-08	Direct	0	Reported balance After 2024-03-18 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2024-03-18 · Disposition to issuer · Disposed 22,800 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers.

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3: Reflects a transfer on March 11, 2024 of 31,518 shares of common stock from the reporting person's direct ownership to a trust of which the reporting person is sole trustee and sole beneficiary. Such transfer was exempt from Section 16 pursuant to Rule 16a-13.

F4: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F5: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F6: These Options are fully vested.

F7: These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F8: These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

F9: These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	175	$178.60	$31,255.00	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 11 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	825	$177.58	$146,503.50	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 10 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F9 · price: Sale prices ranged from $177.12 to $178.00. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	526	$176.51	$92,844.26	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F8 · price: Sale prices ranged from $176.04 to $176.88. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	90	$174.33	$15,689.70	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 8 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,526 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	642	$173.06	$111,104.52	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 7 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,616 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F7 · price: Sale prices ranged from $172.83 to $173.37. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1,434	$172.10	$246,791.40	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 6 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F6 · price: Sale prices ranged from $171.75 to $172.73. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1,235	$171.16	$211,382.60	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 5 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,692 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F5 · price: Sale prices ranged from $170.70 to $171.63. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	4,872	$169.71	$826,827.12	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,927 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F4 · price: Sale prices ranged from $169.32 to $170.28. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	4,948	$168.95	$835,964.60	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,799 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F3 · price: Sale prices ranged from $168.30 to $169.30. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	253	$166.04	$42,008.12	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,747 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. F2 · price: Sale prices ranged from $165.91 to $166.41. Read SEC document
April 01, 2022 Filed Apr 5, 2022 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	15,000	$11.33	$169,950.00	Disclosure SEC source: 0001735276-22-000039 · edgardoc.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 29, 2021. The 15,000 options exercised and sold by the reporting person were due to expire on June 21, 2022. Read SEC document
February 16, 2022 Filed Feb 17, 2022 22:20 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	146,900	$0.00 Strike: $111.97	$0.00	Disclosure SEC source: 0001593968-22-000495 · primary_01.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,900 Underlying: Common Stock · 146,900 shares Expires 2032-02-15 F1 · derivative.exercise_date: 25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. Read SEC document
January 04, 2022 Filed Jan 5, 2022 21:08 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Options (Right to buy) · Derivative	1,638	$0.00 Strike: $42.21	$0.00	Disclosure SEC source: 0001562180-22-000235 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,638 Underlying: Common Stock · 1,638 shares Expires 2032-01-04 F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2022 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2022, subject to the reporting person's continued service through such date. Read SEC document
November 09, 2021 Filed Nov 12, 2021 21:53 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	OtherCommon Stock	1	$43.36	$43.36	Disclosure SEC source: 0001562180-21-007019 · primarydocument.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1 F1 · kind: On November 9, 2021, the Steven Paul Revocable Trust, a family trust of which the reporting person is a trustee (the "Revocable Trust"), withdrew one share of common stock from the Steven M. Paul GRAT VII, a grantor retained annuity trust established for the benefit of the reporting person and his adult children ("GRAT VII"). In exchange for the one share, the Revocable Trust contributed to the GRAT VII $43.36 in cash, which was the closing price of one share of the registrant's common stock on November 9, 2021. The reporting person believes that the withdrawal of the share from GRAT VII constitutes a change in form of beneficial ownership of the share, exempted by Rule 16a-13 under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held directly by the Revocable Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in the Revocable Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
August 18, 2021 Filed Aug 18, 2021 23:43 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	PurchaseCommon Stock	1,181	$106.10	$125,304.10	Disclosure SEC source: 0001593968-21-001992 · primary_01.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 108,849 F1 · kind: The purchases reported on this Form 4 were effected by The Steven M. Paul Revocable Trust. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.95 to $106.13, inclusive. Read SEC document
August 17, 2021 Filed Aug 18, 2021 23:43 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	PurchaseCommon Stock	1,183	$105.63	$124,960.29	Disclosure SEC source: 0001593968-21-001992 · primary_01.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 107,668 F1 · kind: The purchases reported on this Form 4 were effected by The Steven M. Paul Revocable Trust. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.62 to $105.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (2) and (3) to this Form 4. Read SEC document
July 15, 2021 Filed Jul 19, 2021 20:20 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,032	$0.00 Strike: $171.95	$0.00	Disclosure SEC source: 0001735276-21-000066 · edgardoc.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document
June 10, 2021 Filed Jun 11, 2021 20:08 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $76.09	$0.00	Disclosure SEC source: 0001562180-21-004205 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 03, 2021 Filed Jun 4, 2021 20:34 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.23	$0.00	Disclosure SEC source: 0001104659-21-077079 · tm2118780d6_4seq1.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document
February 23, 2021 Filed Feb 24, 2021 22:00 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	161,850	$0.00 Strike: $131.64	$0.00	Disclosure SEC source: 0000899243-21-008030 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,850 Underlying: Common Stock · 161,850 shares Expires 2031-02-22 F1 · derivative.exercise_date: 25% of this option shall vest on February 23, 2022, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:02 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $9.30	$0.00	Disclosure SEC source: 0001735276-20-000109 · edgardoc.xml · derivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020. The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:02 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	15,000	$140.00	$2,100,000.00	Disclosure SEC source: 0001735276-20-000109 · edgardoc.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020. The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021. Read SEC document
December 18, 2020 Filed Dec 22, 2020 21:02 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	15,000	$9.30	$139,500.00	Disclosure SEC source: 0001735276-20-000109 · edgardoc.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020. The 15,000 options exercised and sold by the reporting person were due to expire on June 9, 2021. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:51 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,581	$0.00 Strike: $148.77	$0.00	Disclosure SEC source: 0001735276-20-000078 · edgardoc.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document
June 29, 2020 Filed Jun 30, 2020 20:25 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Exercise / conversionOption (right to buy) · Derivative	292,207	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0001593968-20-001546 · primary_01.xml · derivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 0 Underlying: Common Stock · 292,207 shares Expires 2021-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I. Read SEC document
June 29, 2020 Filed Jun 30, 2020 20:25 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	SaleCommon Stock	292,207	$103.50	$30,243,424.50	Disclosure SEC source: 0001593968-20-001546 · primary_01.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 106,485 F1 · kind: The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I. Read SEC document
June 29, 2020 Filed Jun 30, 2020 20:25 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	Exercise / conversionCommon Stock	292,207	$0.11	$32,142.77	Disclosure SEC source: 0001593968-20-001546 · primary_01.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (1) Disclosed balance after: 398,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale reported on this Form 4 were effected by the The Jann E. Paul Grantor Retained Annuity Trust I. Read SEC document
June 09, 2020 Filed Jun 11, 2020 20:18 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $36.47	$0.00	Disclosure SEC source: 0001562180-20-004430 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
June 04, 2020 Filed Jun 5, 2020 20:16 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $11.79	$0.00	Disclosure SEC source: 0001104659-20-070323 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document
March 31, 2020 Filed Jan 15, 2021 21:05 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GiftStock Option (Right to Buy) · Derivative	292,207	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0000899243-21-002178 · doc5.xml · derivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 292,207 Underlying: Common Stock · 292,207 shares Expires 2021-03-04 F1 · derivative.exercise_date: These shares are fully vested and exercisable. F2 · ownership.nature: This Stock Option (Right to Buy) was gifted to The Jann E. Paul Grantor Retained Annuity Trust I. As previously reported on June 30, 2020, on Form 4, The Jann E. Paul Grantor Retained Annuity Trust I subsequently exercised the Stock Option and sold the underlying shares. Read SEC document
March 31, 2020 Filed Jan 15, 2021 21:05 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GiftStock Option (Right to Buy) · Derivative	292,207	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0000899243-21-002178 · doc5.xml · derivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 0 Underlying: Common Stock · 292,207 shares Expires 2021-03-04 F1 · derivative.exercise_date: These shares are fully vested and exercisable. Read SEC document
March 30, 2020 Filed Jan 15, 2021 21:05 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GiftStock Option (Right to Buy) · Derivative	292,207	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0000899243-21-002178 · doc5.xml · derivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 292,207 Underlying: Common Stock · 292,207 shares Expires 2021-03-04 F1 · derivative.exercise_date: These shares are fully vested and exercisable. Read SEC document
March 30, 2020 Filed Jan 15, 2021 21:05 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GiftStock Option (Right to Buy) · Derivative	292,207	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0000899243-21-002178 · doc5.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 292,207 shares Expires 2021-03-04 F1 · derivative.exercise_date: These shares are fully vested and exercisable. Read SEC document
February 14, 2020 Filed Feb 19, 2020 21:32 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantStock Option (Right to Buy) · Derivative	140,000	$0.00 Strike: $99.72	$0.00	Disclosure SEC source: 0000899243-20-005046 · doc4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: 25% of the options shall vest on February 14, 2021, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. Read SEC document
February 10, 2020 Filed Feb 11, 2020 21:08 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $14.67	$0.00	Disclosure SEC source: 0001735276-20-000010 · edgardoc.xml · derivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-09-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020. F2 · derivative.exercise_date: The stock option vested as to one third of the shares on each of the first, second and third anniversaries of the grant date. Read SEC document
February 10, 2020 Filed Feb 11, 2020 21:08 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	30,000	$130.00	$3,900,000.00	Disclosure SEC source: 0001735276-20-000010 · edgardoc.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020. Read SEC document
February 10, 2020 Filed Feb 11, 2020 21:08 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	30,000	$14.67	$440,100.00	Disclosure SEC source: 0001735276-20-000010 · edgardoc.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019. The 30,000 options exercised and sold by the reporting person were due to expire on September 22, 2020. Read SEC document
July 02, 2019 Filed Jul 2, 2019 21:18 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	ConversionSeries A Preferred Stock · Derivative	74,294	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-018918 · doc4.xml · derivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,485 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date. F1 · price: The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date. Read SEC document
July 02, 2019 Filed Jul 2, 2019 21:18 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	ConversionCommon Stock	96,485	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-018918 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a 1.2987-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock. The Series A Preferred Stock has no expiration date. Read SEC document
July 01, 2019 Filed Jul 2, 2019 20:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $72.01	$0.00	Disclosure SEC source: 0001735276-19-000062 · edgardoc.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document
June 28, 2019 Filed Jul 2, 2019 00:26 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantStock Option (Right to Buy) · Derivative	71,121	$0.00 Strike: $20.02	$0.00	Disclosure SEC source: 0000899243-19-018747 · doc4.xml · derivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,121 Underlying: Common Stock · 71,121 shares Expires 2019-06-28 F3 · derivative.exercise_date: At time of each grant, 65% of the shares underlying the grant were vested, with the remaining vesting in equal monthly installments through June 15, 2021. Read SEC document
June 28, 2019 Filed Jul 2, 2019 00:26 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	PurchaseCommon Stock	3,200	$23.43	$74,976.00	Disclosure SEC source: 0000899243-19-018747 · doc4.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $23.48, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 28, 2019 Filed Jul 2, 2019 00:26 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	PurchaseCommon Stock	6,800	$22.86	$155,448.00	Disclosure SEC source: 0000899243-19-018747 · doc4.xml · nonDerivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.31 to $23.21, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 27, 2019 Filed Jul 2, 2019 00:26 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantStock Option (Right to Buy) · Derivative	616,703	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-19-018747 · doc4.xml · derivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,703 Underlying: Common Stock · 616,703 shares Expires 2019-06-27 F3 · derivative.exercise_date: At time of each grant, 65% of the shares underlying the grant were vested, with the remaining vesting in equal monthly installments through June 15, 2021. Read SEC document
June 13, 2019 Filed Jun 17, 2019 23:01 UTC	Voyager Therapeutics, Inc. VYGR · Entity 6271	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $24.68	$0.00	Disclosure SEC source: 0001104659-19-036005 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document
June 05, 2019 Filed Jun 6, 2019 20:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $177.41	$0.00	Disclosure SEC source: 0001562180-19-003395 · primarydocument.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
March 21, 2019 Filed Mar 22, 2019 20:22 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	1,967	$161.02	$316,726.34	Disclosure SEC source: 0001562180-19-002013 · primarydocument.xml · nonDerivative · entry 4 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (6) Disclosed balance after: 122,400 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · kind: Represents 30,600 shares held directly by the McGill Trust; 30,600 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 30600 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F7 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.15 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 21, 2019 Filed Mar 22, 2019 20:22 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	2,919	$161.05	$470,104.95	Disclosure SEC source: 0001562180-19-002013 · primarydocument.xml · nonDerivative · entry 3 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (4) Disclosed balance after: 124,367 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · kind: Represents 30,600 shares held directly by the McGill Trust; 30,600 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F5 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.21 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 21, 2019 Filed Mar 22, 2019 20:22 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	2,993	$161.04	$481,992.72	Disclosure SEC source: 0001562180-19-002013 · primarydocument.xml · nonDerivative · entry 2 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (2) Disclosed balance after: 127,286 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · kind: Represents 30,600 shares held directly by the McGill Trust; 33,519 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F3 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $161.20 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
March 20, 2019 Filed Mar 21, 2019 00:47 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	13,047	$161.35	$2,105,133.45	Disclosure SEC source: 0001562180-19-001988 · primarydocument.xml · nonDerivative · entry 9 PAUL STEVEN M · CIK 0001237564 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote (16) Disclosed balance after: 130,279 F1 · kind: The sales reported on this Form 4 were effected by the Aaron Paul Trust, the Austin Paul Trust, the Jordan Fisch Trust and the McGill Trust pursuant to trading plans adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · kind: Represents 33,593 shares held directly by the McGill Trust; 33,519 shares held directly by the Jordan Fisch Trust; 30,600 shares held directly by the Aaron Paul Trust; and 32,567 shares held directly by the Austin Paul Trust. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. F17 · price: This transaction was executed in multiple trades at prices ranging from $161.00 USD to $162.46 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.